Factor 8 SHL denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for factor 8 shl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Factor VIII (SHL) for Prior Authorization Required

Blue Cross Blue Shield requires prior authorization (PA) for extended half-life (SHL) Factor VIII products before dispensing. A prior-auth-required denial means the medication was dispensed or billed without a PA on file, or the PA request was incomplete, was not obtained in time, or was denied on clinical grounds.

This is one of the most common — and most resolvable — denial types for specialty hemophilia products. The path forward depends on whether you need a retroactive authorization (for care already received) or a prospective authorization (for ongoing treatment).

## Federal Appeal Rights

• ERISA §503: employer-plan members may appeal a PA denial as a medical-necessity decision, with full-and-fair internal review.
• ACA §2719: if the PA denial is upheld internally, you may request independent external review through an IRO.
• You generally have approximately four months from the denial date to initiate external review.
• Expedited review: if your hematologist certifies that waiting for a standard PA decision poses a serious health risk (e.g., active bleeding risk), request expedited PA review and parallel expedited appeal.

## Concrete Appeal Timeline

1. Determine the denial sub-type: was PA simply not obtained (administrative), or was it denied after clinical review? - Administrative: submit a retroactive PA request with full clinical documentation immediately. - Clinical denial: file a formal appeal with the documentation below. 2. File the internal appeal within the timeframe on your EOB. 3. If denied, escalate to external review without delay.

## Documentation to Gather

• Diagnosis and severity records: hematology records with FVIII activity levels, inhibitor status, bleeding history, and severity classification.
• Prior treatment history: all previous Factor VIII products used, with dates, documented outcomes, and rationale for transition to SHL formulation.
• Pharmacokinetic data: if PK profiling was performed, include those results and your hematologist's interpretation.
• Urgency documentation: if treatment was initiated without PA due to an acute bleeding event or clinical emergency, document that clinical urgency in the record.
• Prescriber medical-necessity letter: addresses each PA criterion in BCBS's published prior-authorization policy for Factor VIII SHL products.
• Annualized bleed rate and functional status: chart-documented bleed history and any joint or organ damage.

## Criteria-Mapping Structure

Obtain BCBS's current prior-authorization criteria for extended half-life Factor VIII products and map each requirement to your chart:

| PA Criterion | Supporting Documentation | |---|---| | Confirmed hemophilia A diagnosis | [Lab records, dates] | | Prescribing hematologist | [Provider name and specialty] | | Prior Factor VIII product trial (if required) | [Product, dates, outcomes from chart] | | Clinical justification for SHL over standard | [PK data or hematologist's individualized rationale] |

Verify the exact current PA criteria directly from BCBS's published utilization-management or prior-authorization guidelines for Factor VIII, and confirm all clinical requirements against the FDA-approved prescribing information. PA criteria are updated regularly; use the version in effect on the date of denial.